The following is a summary of “An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal ...

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

Even though the gallbladder is often forgotten, it is vital to everyone's overall health to keep it functioning well.

It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various ...

NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings ...

Conversely, among the 37 human metabolites were found to reduce the risk of coronary atherosclerosis, the following were included: Cholesteryl esters to total lipids ratio in medium HDL: The OR for ...

This paper presents the important discovery that lipid metabolic imbalance caused by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells.

After hours: December 20 at 6:27:33 PM EST Loading Chart for NAMS ...

Norrish and Kirkbride, J. Chem. Soc., 1518 (1932). Norrish and Appleyard, J. Chem. Soc., 874 (1934). Norrish, Crone and Saltmarsh, J. Chem. Soc., 1456 (1934). Spence ...

Another enzyme, cholesteryl ester transfer protein, mediates the transfer of cholesterol ester from the HDL core and other circulating lipoproteins such as LDL. [12] Several apolipoproteins have ...

Cardiovascular outcomes trials with experimental cholesteryl ester transfer protein inhibitors will provide crucial data on the viability of pharmacological strategies to raise HDL-cholesterol.